Links and Resources

• 2018 TATFAR meeting opening session
• 2017 Pull Incentives for Antibacterial Drug Development: An Analysis by the TATFAR
• 2016 Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations from the TATFAR
• 2016 Economic Incentives for Antimicrobial Therapy Development: Summary from the TATFAR [PDF – 28 pages] (Full Report) 2016 Report on Recommendation 18 [PDF – 33 pages]
• 2015  Report on the modified Delphi process for common structure and process indicators for hospital antimicrobial stewardship programs [PDF – 1.7 MB]
• 2014 TATFAR Progress report [ PDF – 86 pages ]
• 2011 TATFAR Report [ PDF – 47 pages ]
• 2011 EU-U.S. Workshop Report [ PDF – 13 pages ]
• 2009 EU-U.S. Summit Declaration [ PDF – 6 pages ]

Antibiotic Resistance Action Plans

• Norwegian National Strategy Against Antibiotic Resistance 2015-2020
• Tackling Antimicrobial Resistance and Antimicrobial Use: A Pan-Canadian Framework for Action
• A European One Health Action Plan against Antimicrobial Resistance (AMR)
• United States National Action Plan for Combating Antibiotic-Resistant Bacteria [PDF – 63 pages]
  • Progress Report for Years 1 and 2

 Centers for Disease Control and Prevention

• Antibiotic Use in the United States, 2017: Progress and Opportunities
• Antibiotic Resistant Threats in the United States, CDC, 2013 [PDF – 114 pages]

European Commission

• A European One Health Action Plan against Antimicrobial Resistance, 2017 [PDF – 24 pages]
• Progress report on the Action plan against the rising threats from Antimicrobial
  Resistance, 2015 [PDF – 47 pages]
• Action plan against the rising threats from Antimicrobial Resistance, 2011 [PDF – 17 pages]

European Centre for Disease Prevention and Control

• ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals, 2017 [PDF – 135 pages]
• ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals, 2015 [PDF – 114 pages]
• Antimicrobial Resistance in Europe, ECDC, 2011 [PDF- 208 pages]
• The Bacterial Challenge: Time to React, ECDC, 2009 [PDF-54 pages]

European Food Safety Authority

• EFSA/ECDC European Union summary report on antimicrobial resistance in zoonotic indicator bacteria from humans, animals and food in 2013, 2015 [PDF – 178 pages]
• Fact Sheet on Antimicrobial Resistance [PDF- 2 pages]

European Medicines Agency

• Report on the event “Best use of medicines legislation to bring new antibiotics to patients and combat the resistance problem” [PDF-4 pages]

U.S. Food and Drug Administration

• Guidance for Industry #209, The Judicious Use of Medically Important Antibiotics in Food Producing Animals, FDA, 2012 [PDF-26 pages]

U.S. National Institute of Allergy and Infectious Diseases

• NIAID’s Antibacterial Resistance Program: Current Status and Future Directions, NIAID, 2014 [PDF-15 pages]

These are funding opportunities from TATFAR Members.

• European Commission-DG RTD
• NIH, Antimicrobial Resistance Funding
  • Partnerships Program for Translational Research
    • Vaccines and Immunoprophylactics (closes Oct 4, 2017)
    • Clinically useful diagnostics (closes Oct 4, 2017)
    • Therapeutics and vaccines for priority pathogens, including resistant bacteria and fungi (closes Jan 12, 2018)
• Horizon 2020
• Innovative Medicines Initiative
• Joint Programming Initiative on AMR